Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...2526272829303132333435...123124»
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Metabolic Plasticity is One of the Mechanisms of Thyroid Cancer Resistance to Lenvatinib () -  Sep 20, 2023 - Abstract #ATA2023ATA_256;    
    Enhanced mitochondrial respiration is one of the contributing factors towards resistance to Lenvatinib. Combination therapies including OXPHOS inhibitors should be tested as potential avenues to overcome metabolic resistance mechanisms.
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Metastases:  Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC (clinicaltrials.gov) -  Sep 14, 2023   
    P2,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial primary completion date:  Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment (clinicaltrials.gov) -  Sep 13, 2023   
    P=N/A,  N=200, Enrolling by invitation, 
    The MAPS-CRAFITY score based on sarcopenia and the CRAFITY score is a reliable and practical tool for predicting the efficacy of targeted therapy plus immunotherapy in patients with unresectable HCC, and may help hepatologists and oncologists in clinical decision-making. Trial primary completion date: Jul 2023 --> Dec 2024
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. (Pubmed Central) -  Sep 11, 2023   
    In conclusion, Bevacizumab is a drug resistant treatment option for patients with advanced hepatocellular carcinoma after Lenva+PD-1/PD-L1 treatment. Atezolizumab plus bevacizumab and, more recently, durvalumab plus tremelimumab have entered the clinical practice and are the current standard of care for treatment-na
  • ||||||||||  fostroxacitabine bralpamide (MIV-818) / Medivir
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  MIV-818-101: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations (clinicaltrials.gov) -  Sep 11, 2023   
    P1/2,  N=53, Active, not recruiting, 
    TACE-L-P has more promising clinical outcomes in patients with uHCC than TACE-L, and their safety is similar. Recruiting --> Active, not recruiting | N=102 --> 53 | Trial completion date: May 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Biomarker, Review, Journal:  Emerging role of exosome-shuttled noncoding RNAs in gastrointestinal cancers: from intercellular crosstalk to clinical utility. (Pubmed Central) -  Sep 11, 2023   
    Moreover, exosomes are increasingly recognized as natural delivery vehicles for ncRNA-based therapeutic interventions. In this review, we elucidate the processes of ncRNA-enriched exosome biogenesis and uptake, examine the regulatory and functional roles of exosomal ncRNA-mediated intercellular crosstalk in gastrointestinal TME and tumor behaviors, and explore their potential clinical utility in diagnostics, prognostics, and therapeutics.
  • ||||||||||  Biomarker, Review, Journal, IO biomarker:  Potential Predictive Biomarkers of Systemic Drug Therapy for Hepatocellular Carcinoma: Anticipated Usefulness in Clinical Practice. (Pubmed Central) -  Sep 9, 2023   
    Subsequently, cabozantinib, another TKI, was introduced as a second-line treatment, along with ramucirumab, the only drug proven to be predictive of therapeutic efficacy when AFP levels are >400 ng/mL...Additionally, there are no practical biomarkers to predict their therapeutic effects. Therefore, this review provides an overview of extensive research conducted on potential HCC biomarkers from blood, tissue, or imaging information that can be used in practice to predict the therapeutic efficacy of systemic therapy before its initiation.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Retrospective data, Journal, Metastases:  Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis. (Pubmed Central) -  Sep 7, 2023   
    Utilizing ILA@Lip is a profound strategy to create an extremely hypoxic tumor microenvironment for higher therapeutic efficacy of hypoxia-activated chemotherapy, which realized collective suppression of tumor growth and has promising potential for clinical translation. Compared with TACE or lenvatinib alone, TACE plus lenvatinib has achieved remarkable efficacy in patients with advanced HCC, and the efficacy versus risk need to be carefully balanced in clinical application.
  • ||||||||||  volrustomig (MEDI5752) / AstraZeneca
    Enrollment change:  A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) -  Aug 31, 2023   
    P1b,  N=179, Recruiting, 
    Compared with TACE or lenvatinib alone, TACE plus lenvatinib has achieved remarkable efficacy in patients with advanced HCC, and the efficacy versus risk need to be carefully balanced in clinical application. N=70 --> 179
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date:  Neo PeLeMM: Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (clinicaltrials.gov) -  Aug 30, 2023   
    P2,  N=44, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: May 2023 --> Oct 2023